{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T01:06:50Z","timestamp":1761959210639,"version":"build-2065373602"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T00:00:00Z","timestamp":1558656000000},"content-version":"vor","delay-in-days":143,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009954","name":"Taiho Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009954","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013170","name":"Ono Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013170","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine Case Reports"],"published-print":{"date-parts":[[2019]]},"DOI":"10.1016\/j.rmcr.2019.100862","type":"journal-article","created":{"date-parts":[[2019,5,26]],"date-time":"2019-05-26T09:36:18Z","timestamp":1558863378000},"page":"100862","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["A case of successful concurrent anti-cancer treatment in a patient who developed follicular lymphoma during treatment with afatinib for advanced lung adenocarcinoma"],"prefix":"10.1016","volume":"28","author":[{"given":"Kentaro","family":"Masuhiro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Genju","family":"Koh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"So","family":"Takata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shingo","family":"Nasu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromune","family":"Takada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satomu","family":"Morita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayako","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Shiroyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoko","family":"Morishita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidekazu","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norio","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromi","family":"Kawasumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chihiro","family":"Konishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomonori","family":"Hirashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmcr.2019.100862_bib1","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1093\/annonc\/mds214","article-title":"North-East Japan Study Group, Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-na\u00efve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002)","volume":"24","author":"Inoue","year":"2012","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.rmcr.2019.100862_bib2","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"FLAURA Investigators, Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.rmcr.2019.100862_bib3","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"ALEX Trial Investigators, Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.rmcr.2019.100862_bib4","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jtho.2015.09.009","article-title":"The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer","volume":"11","author":"Goldstraw","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.rmcr.2019.100862_bib5","first-page":"1860","article-title":"Report of the committee on Hodgkin's disease staging classification","volume":"31","author":"Carbone","year":"1971","journal-title":"Cancer Res."},{"key":"10.1016\/j.rmcr.2019.100862_bib6","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1200\/JCO.2008.21.3991","article-title":"Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project","volume":"27","author":"Federico","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.rmcr.2019.100862_bib7","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1182\/blood-2006-03-013193","volume":"108","author":"Sebban","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.rmcr.2019.100862_bib8","first-page":"1358","article-title":"Multiple primary malignant tumors: a survey of the literature and a statistical study","volume":"16","author":"Warren","year":"1932","journal-title":"Am. J. Cancer"},{"key":"10.1016\/j.rmcr.2019.100862_bib9","first-page":"1152","article-title":"Second primary tumors involving non-small cell lung cancer: prevalence and its influence on survival","volume":"127","author":"Duchateau","year":"2005","journal-title":"Chest"},{"key":"10.1016\/j.rmcr.2019.100862_bib10","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.ejcts.2008.08.004","article-title":"Multiple independent primary cancers do not adversely affect survival of the lung cancer patient","volume":"34","author":"Aguil\u00f3","year":"2008","journal-title":"Eur. J. Cardiothorac. Surg."},{"key":"10.1016\/j.rmcr.2019.100862_bib11","first-page":"737","article-title":"Characteristics of additional primary malignancies in Korean patients with non-small cell lung cancer","volume":"5","author":"Son","year":"2013","journal-title":"J. Thorac. Dis."},{"key":"10.1016\/j.rmcr.2019.100862_bib12","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.jtcvs.2003.10.039","article-title":"Risk of subsequent primary neoplasms developing in lung cancer patients with prior malignancies","volume":"127","author":"Brock","year":"2004","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"10.1016\/j.rmcr.2019.100862_bib13","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0169-5002(01)00408-1","article-title":"Multiple primary malignancies involving lung cancer\u2013clinical characteristics and prognosis","volume":"35","author":"Liu","year":"2002","journal-title":"Lung Cancer"},{"key":"10.1016\/j.rmcr.2019.100862_bib14","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0959-8049(00)00428-7","article-title":"Risk of a new primary cancer among patients with lung cancer of different histological types","volume":"37","author":"Teppo","year":"2001","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.rmcr.2019.100862_bib15","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/(SICI)1097-0142(19990701)86:1<186::AID-CNCR25>3.0.CO;2-3","article-title":"Second primary cancers in patients with lung carcinoma","volume":"86","author":"Levi","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/j.rmcr.2019.100862_bib16","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.athoracsur.2010.02.114","article-title":"Non-small cell lung cancer resection in lymphoma patients","volume":"90","author":"Kim","year":"2010","journal-title":"Ann. Thorac. Surg."},{"key":"10.1016\/j.rmcr.2019.100862_bib17","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1093\/annonc\/mdw611","article-title":"Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial","volume":"28","author":"Paz-Ares","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.rmcr.2019.100862_bib18","first-page":"1145","article-title":"Bone marrow involvement is predictive of infusion-related reaction during rituximab administration in patients with B cell lymphoma, Support","volume":"21","author":"Hong","year":"2013","journal-title":"Care Cancer"},{"key":"10.1016\/j.rmcr.2019.100862_bib19","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1182\/blood.V94.7.2217.419k02_2217_2224","article-title":"Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8)","volume":"94","author":"Winkler","year":"1999","journal-title":"Blood"}],"container-title":["Respiratory Medicine Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213007119300528?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213007119300528?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T01:02:17Z","timestamp":1761958937000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213007119300528"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"references-count":19,"alternative-id":["S2213007119300528"],"URL":"https:\/\/doi.org\/10.1016\/j.rmcr.2019.100862","relation":{},"ISSN":["2213-0071"],"issn-type":[{"type":"print","value":"2213-0071"}],"subject":[],"published":{"date-parts":[[2019]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A case of successful concurrent anti-cancer treatment in a patient who developed follicular lymphoma during treatment with afatinib for advanced lung adenocarcinoma","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmcr.2019.100862","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100862"}}